The estimated Net Worth of Schutter Richard U De is at least $6.94 Million dollars as of 4 August 2021. Mr. De owns over 10,000 units of Bausch Health Companies Inc stock worth over $2,023,155 and over the last 20 years he sold BHC stock worth over $4,546,000. In addition, he makes $375,000 as Independent Director at Bausch Health Companies Inc.
Sign up
Mr. Schutter BHC stock SEC Form 4 insiders trading
Richard has made over 19 trades of the Bausch Health Companies Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of BHC stock worth $250,100 on 4 August 2021.
The largest trade he's ever made was buying 125,000 units of Bausch Health Companies Inc stock on 13 September 2018 worth over $2,995,000. On average, Richard trades about 6,304 units every 65 days since 2004. As of 4 August 2021 he still owns at least 317,109 units of Bausch Health Companies Inc stock.
You can see the complete history of Mr. De stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard De Schutter biography
Richard (Dick) U. De Schutter is an Independent Director of the Company. Mr. De Schutter has served on the Board since January 2017. He is currently a corporate director. Prior to his retirement, Mr. De Schutter served as the Chairman and CEO of DuPont Pharmaceuticals Company from July 2000 until its acquisition by Bristol-Myers Squibb in October 2001. Mr. De Schutter was also a director and Chief Administrative Officer of Pharmacia Corporation, which was created through the merger of Monsanto Company and Pharmacia & Upjohn in 2000. Prior to this merger, Mr. De Schutter was a director, Vice Chairman and Chief Administrative Officer for Monsanto. From 1995 to 1999, he served as Chairman and CEO of G.D. Searle & Co., Monsanto’s wholly owned pharmaceutical subsidiary. Mr. De Schutter earned a Bachelor of Science degree in 1963, and a Master of Science Degree in Chemical Engineering in 1965 from the University of Arizona. Mr. De Schutter has served as a director of AuVen Therapeutics, a private equity company focused on the healthcare industry, since 2007. He has also served as a director of Applied Silver, Inc., a private biotechnology company, since 2016, and has served as a director of Sermonix Pharmaceuticals Inc., a private biotechnology company, since April 2019. He previously served as Chairman of Incyte Corporation, a pharmaceutical company, from 2003 to 2015.
What is the salary of Richard Schutter?
As the Independent Director of Bausch Health Companies Inc, the total compensation of Richard Schutter at Bausch Health Companies Inc is $375,000. There are 17 executives at Bausch Health Companies Inc getting paid more, with Joseph Papa having the highest compensation of $17,141,600.
How old is Richard Schutter?
Richard Schutter is 79, he's been the Independent Director of Bausch Health Companies Inc since 2017. There are no older and 22 younger executives at Bausch Health Companies Inc.
What's Richard Schutter's mailing address?
Schutter's mailing address filed with the SEC is 400 SOMERSET CORPORATE BOULEVARD, , BRIDGEWATER, NJ, 08807.
Insiders trading at Bausch Health Companies Inc
Over the last 6 years, insiders at Bausch Health Companies Inc have traded over $2,786,244 worth of Bausch Health Companies Inc stock and bought 6,317,686 units worth $110,094,785 . The most active insiders traders include John Paulson, Argeris N Karabelas, and Brett Icahn. On average, Bausch Health Companies Inc executives and independent directors trade stock every 36 days with the average trade being worth of $824,564. The most recent stock trade was executed by Seana Carson on 5 September 2024, trading 13,370 units of BHC stock currently worth $83,028.
What does Bausch Health Companies Inc do?
bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###
What does Bausch Health Companies Inc's logo look like?
Complete history of Mr. De stock trades at Incyte, Ecolab, and Bausch Health Companies Inc
Bausch Health Companies Inc executives and stock owners
Bausch Health Companies Inc executives and other stock owners filed with the SEC include:
-
Joseph Papa,
Chairman of the Board, Chief Executive Officer -
Paul Herendeen,
Chief Financial Officer, Executive Vice President -
Joseph C. Papa,
CEO & Chairman -
Thomas Appio,
President & Co-Head Bausch + Lomb/International -
William Humphries,
-
Christina Ackermann,
Executive Vice President, General Counsel -
Thomas J. Appio,
Pres & Co-Head Bausch + Lomb/International -
Paul S. Herendeen,
Exec. VP and Advisor to Chairman & CEO -
Joseph Gordon,
President & Co-Head Bausch + Lomb/International -
Christina M. Ackermann,
Exec. VP, Gen. Counsel & Head of Commercial Operations -
Thomas Ross,
Lead Independent Director -
Russel Robertson,
Independent Director -
Robert Power,
Independent Director -
Argeris Karabelas,
Independent Director -
Sarah Kavanagh,
Independent Director -
D. Robert Hale,
Independent Director -
Amy Wechsler,
Independent Director -
Richard De Schutter,
Independent Director -
Andrew Charles von Eschenbach,
Independent Director -
John Paulson,
Independent Director -
Tom G. Vadaketh,
Chief Financial Officer -
Frederick J. Munsch,
Controller & Chief Accounting Officer -
Kelly Webber,
Sr. VP & Chief HR Officer -
Stacey Williams,
VP of Marketing -
Michael McMyne,
VP of Sales -
Arthur J. Shannon,
Sr. VP and Head of Investor Relations & Communications -
Dr. Robert F. Butz,
VP of Medical & Scientific Affairs -
Osama A. Eldessouky,
CFO & Exec. VP -
Christian A Garcia,
Director -
Frank D. Lee,
Director -
Mark C. Mc Kenna,
President, Salix -
Holdings, L.P.Value Act Hol...,
-
Brett Icahn,
Director -
Steven D Miller,
Director -
Tom George Vadaketh,
EVP, Chief Financial Officer -
Holdings, L.P.Value Act Cap...,
-
Aimee J. Lenar,
EVP, US Pharma -
Seana Carson,
EVP, General Counsel -
David Robert Value Act Hold...,
-
Sam Eldessouky,
EVP & Chief Financial Officer -
Frederick Munsch,
SVP, Controller and CAO -
Robert Spurr,
President, U.S. Businesses -
Richard Mulligan,
Director -
John S Barresi,
SVP, Controller & CAO -
Jean Jacques Charhon,
EVP, CFO